Skip to content
Screener

AnaptysBio, Inc. ANAB Pre-Tax Income

Pre-Tax Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.09B+130%
Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%
Pfizer logo
PfizerPFE
-$653M-121%
Amgen logo
AmgenAMGN
$2.77B+76.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.53B+0.6%
Biogen logo
BiogenBIIB
$132.4M-82.2%

Segments

By segment

See full
Biopharma Company-$50.48M
Royalty Management Company-$2.36M

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Non-cash interest expense for the sale of future royalties(20,859)(18,061)
Other (expense) income, net(1)1,902
Total other expense, net(18,207)(11,746)
Loss before income taxes(52,844)(39,285)
Provision for income taxes(40)(44)
Net loss(52,884)(39,329)
Other comprehensive loss:
Unrealized loss on available-for-sale securities(122)(144)

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s pre-tax income?
AnaptysBio, Inc. (ANAB) reported pre-tax income of -$52.84M in Q1 2026.
How has AnaptysBio, Inc.'s pre-tax income changed year-over-year?
AnaptysBio, Inc.'s pre-tax income decreased by 34.5% year-over-year, from -$39.29M to -$52.84M.
What is the long-term trend for AnaptysBio, Inc.'s pre-tax income?
Over 3 years (2021 to 2024), AnaptysBio, Inc.'s pre-tax income has grown at a 36.0% compound annual growth rate (CAGR), from -$57.8M to -$145.23M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about AnaptysBio, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude